Page 1853 - Williams Hematology ( PDFDrive )

1828 Part XII: Hemostasis and Thrombosis <CN>: <CT> PB

167. Laiho M, DeCaprio JA, Ludlow JW, et al: Growth inhibition by TGF-beta linked to 198. Tichelli A, Gratwohl A, Berger C, et al: Treatment of thrombocytosis in myeloprolifer-
suppression of retinoblastoma protein phosphorylation. Cell 62:175, 1990. ative disorders with interferon alpha-2a. Blut 58:15, 1989.
168. Polyak K, Kato JY, Solomon MJ, et al: P27Kip1, a cyclin-Cdk inhibitor, links transform- 199. Gisslinger H, Ludwig H, Linkesch W, et al: Long-term interferon therapy for thrombo-
ing growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8:9, 1994. cytosis in myeloproliferative diseases. Lancet 1:634, 1989.
169. Teofili L, Martini M, Di Mario A, et al: Expression of p15(ink4b) gene during megakary- 200. Sacchi S, Gugliotta L, Papineschi F, et al: Alfa-interferon in the treatment of essen-
ocytic differentiation of normal and myelodysplastic hematopoietic progenitors. Blood tial thrombocythemia: Clinical results and evaluation of its biological effects on the
98:495, 2001. hematopoietic neoplastic clone. Italian Cooperative Group on ET. Leukemia 12:289,
170. Theofilopoulos AN, Baccala R, Beutler B, Kono DH: Type I interferons (alpha/beta) in 1998.
immunity and autoimmunity. Annu Rev Immunol 23:307, 2005. 201. Taylor PC, Dolan G, Ng JP, et al: Efficacy of recombinant interferon-alpha (rIFN-alpha)
171. Broxmeyer HE, Cooper S, Rubin BY, Taylor MW: The synergistic influence of human in polycythaemia vera: A study of 17 patients and an analysis of published data. Br J
interferon-gamma and interferon-alpha on suppression of hematopoietic progenitor Haematol 92:55, 1996.
cells is additive with the enhanced sensitivity of these cells to inhibition by interferons 202. Tornebohm-Roche E, Merup M, Lockner D, Paul C: Alpha-2a interferon therapy and
at low oxygen tension in vitro. J Immunol 135:2502, 1985. antibody formation in patients with essential thrombocythemia and polycythemia vera
172. Fattovich G, Giustina G, Favarato S, Ruol A: A survey of adverse events in 11,241 with thrombocytosis. Am J Hematol 48:163, 1995.
patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 24:38, 1996. 203. Hokom MM, Lacey D, Kinstler OB, et al: Pegylated megakaryocyte growth and devel-
173. Dusheiko G: Side effects of alpha interferon in chronic hepatitis C. Hepatology 26(Suppl opment factor abrogates the lethal thrombocytopenia associated with carboplatin and
1):112S, 1997. irradiation in mice. Blood 86:4486, 1995.
174. Jaster R, Tschirch E, Bittorf T, Brock J: Interferon-alpha inhibits proliferation of Ba/F3 204. Fibbe WE, Heemskerk DP, Laterveer L, et al: Accelerated reconstitution of platelets
cells by interfering with interleukin-3 action. Cell Signal 11:769, 1999. and erythrocytes after syngeneic transplantation of bone marrow cells derived from
175. Kuniyasu H, Yasui W, Kitahara K, et al: Growth inhibitory effect of interferon-beta is thrombopoietin pretreated donor mice. Blood 86:3308, 1995.
associated with the induction of cyclin-dependent kinase inhibitor p27Kip1 in a human 205. Molineux G, Hartley C, McElroy P, et al: Megakaryocyte growth and development fac-
gastric carcinoma cell line. Cell Growth Differ 8:47, 1997. tor accelerates platelet recovery in peripheral blood progenitor cell transplant recipi-
176. Wang Q, Miyakawa Y, Fox N, Kaushansky K: Interferon-alpha directly represses ents. Blood 88:366, 1996.
megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction 206. Fanucchi M, Glaspy J, Crawford J, et al: Effects of polyethylene glycol conjugated
of SOCS-1. Blood 96:2093, 2000. recombinant human megakaryocyte growth and development factor on platelet counts
177. Long MW: Blood cell cytoadhesion molecules. Exp Hematol 20:288, 1992. after chemotherapy for lung cancer. N Engl J Med 336:404, 1997.
178. Toksoz D, Zsebo KM, Smith KA, et al: Support of human hematopoiesis in long- 207. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al: Stimulation of megakaryocyte and
term bone marrow cultures by murine stromal cells selectively expressing the mem- platelet production by a single dose of recombinant human thrombopoietin in patients
brane-bound and secreted forms of the human homolog of the steel gene product, stem with cancer. Ann Intern Med 126:673, 1997.
cell factor. Proc Natl Acad Sci U S A 89:7350, 1992. 208. Basser RL, Underhill C, Davis I, et al: Enhancement of platelet recovery after myelosup-
179. Yang L, Yang YC: Regulation of interleukin (IL)-11 gene expression in IL-1 induced pressive chemotherapy by recombinant human megakaryocyte growth and develop-
primate bone marrow stromal cells. J Biol Chem 269:32732, 1994. ment factor in patients with advanced cancer. J Clin Oncol 18:2852, 2000.
180. Linenberger ML, Jacobson FW, Bennett LG, et al: Stem cell factor production by human 209. Archimbaud E, Ottmann OG, Yin JA, et al: A randomized, double-blind, placebo-
marrow stromal fibroblasts. Exp Hematol 23:1104, 1995. controlled study with pegylated recombinant human megakaryocyte growth and
181. Gordon MY, Riley GP, Watt SM, Greaves MF: Compartmentalization of a haematopoi- development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with
etic growth factor (GM-CSF) by glycosaminoglycans in the bone marrow microenvi- de novo acute myeloid leukemia. Blood 94:3694, 1999.
ronment. Nature 326:403, 1987. 210. Bolwell B, Vredenburgh J, Overmoyer B, et al: Phase 1 study of pegylated recombinant
182. Roberts R, Gallagher J, Spooncer E, et al: Heparan sulphate bound growth factors: A human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast
mechanism for stromal cell mediated haemopoiesis. Nature 332:376, 1988. cancer patients after autologous peripheral blood progenitor cell (PBPC) transplanta-
183. Artavanis-Tsakonas S, Matsuno K, Fortini ME: Notch signaling. Science 268:225, 1995. tion. Bone Marrow Transplant 26:141, 2000.
184. Karanu FN, Murdoch B, Miyabayashi T, et al: Human homologues of Delta-1 and 211. Somlo G, Sniecinski I, Ter Veer A, et al: Recombinant human thrombopoietin in com-
Delta-4 function as mitogenic regulators of primitive human hematopoietic cells. Blood bination with granulocyte colony-stimulating factor enhances mobilization of periph-
97:1960, 2001. eral blood progenitor cells, increases peripheral blood platelet concentration, and
185. Lam LT, Ronchini C, Norton J, et al: Suppression of erythroid but not megakary- accelerates hematopoietic recovery following high-dose chemotherapy. Blood 93:2798,
ocytic differentiation of human K562 erythroleukemic cells by notch-1. J Biol Chem 1999.
275:19676, 2000. 212. Nomura S, Dan K, Hotta T, et al: Effects of pegylated recombinant human megakary-
186. Fox NE, Kaushansky K: Engagement of integrin a4b1 enhances thrombopoietin- ocyte growth and development factor in patients with idiopathic thrombocytopenic
induced megakaryopoiesis. Exp Hematol 33:94, 2005. purpura. Blood 100:728, 2002.
187. Bruno E, Briddell RA, Cooper RJ, Hoffman R: Effects of recombinant interleukin 11 on 213. Vadhan-Raj S, Patel S, Bueso-Ramos C, et al: Importance of predosing of recombinant
human megakaryocyte progenitor cells. Exp Hematol 19:378, 1991. human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia.
188. Neben S, Turner K: The biology of interleukin 11. Stem Cells 11(Suppl 2):156, 1993. J Clin Oncol 21:3158, 2003.
189. Burstein SA, Mei RL, Henthorn J, et al: Leukemia inhibitory factor and interleukin-11 214. Li J, Yang C, Xia Y, et al: Thrombocytopenia caused by the development of antibodies to
promote maturation of murine and human megakaryocytes in vitro. J Cell Physiol thrombopoietin. Blood 98:3241, 2001.
153:305, 1992. 215. Kimura T, Kaburaki H, Tsujino T, et al: A non-peptide compound which can mimic the
190. Yonemura Y, Kawakita M, Masuda T, et al: Synergistic effects of interleukin 3 and interleu- effect of thrombopoietin via c-Mpl. FEBS Lett 428:250, 1998.
kin 11 on murine megakaryopoiesis in serum-free culture. Exp Hematol 20:1011, 1992. 216. de Serres M, Yeager RL, Dillberger JE, et al: Pharmacokinetics and hematological effects
191. Yonemura Y, Kawakita M, Masuda T, et al: Effect of recombinant human interleukin-11 of the PEGylated thrombopoietin peptide mimetic GW395058 in rats and monkeys
on rat megakaryopoiesis and thrombopoiesis in vivo: Comparative study with interleu- after intravenous or subcutaneous administration. Stem Cells 17:316, 1999.
kin-6. Br J Haematol 84:16, 1993. 217. Broudy VC, Lin NL: AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl.
192. Schlerman FJ, Bree AG, Kaviani MD, et al: Thrombopoietic activity of recombinant Cytokine 25:52, 2004.
human interleukin 11 (rHuIL-11) in normal and myelosuppressed nonhuman pri- 218. Kaushansky K: Hematopoietic growth factor mimetics. Ann N Y Acad Sci 938:131,
mates. Stem Cells 14:517, 1996. 2001.
193. Gordon MS SG, Battiato L, et al: The in vivo effects of subcutaneously (SC) adminis- 219. Kuter DJ, Bussel JB, Lyons RM, et al: Efficacy of romiplostim in patients with chronic
tered recombinant human interleukin-11 (Neumega rhIL-11 growth factor; rhIL-11) in immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lan-
women with breast cancer (BC). Blood 82(Suppl 1):498a, 1993. cet 371:395, 2008.
194. Champlin RE MR, Kaye JA, et al: Recombinant human interleukin eleven (rhIL-11) 220. Bussel JB, Cheng G, Saleh MN, et al: Eltrombopag for the treatment of chronic idio-
following autologous BMT for breast cancer. Blood 84(suppl 1):395a, 1994. pathic thrombocytopenic purpura. N Engl J Med 357:2237, 2007.
195. Tepler I, Elias L, Smith JW 2nd, et al: A randomized placebo-controlled trial of recom- 221. McHutchison JG, Dusheiko G, Shiffman ML, et al: Eltrombopag for thrombocytopenia
binant human interleukin-11 in cancer patients with severe thrombocytopenia due to in patients with cirrhosis associated with hepatitis C. N Engl J Med 357:2227, 2007.
chemotherapy. Blood 87:3607, 1996. 222. Qin P, Dong X, Li J, et al: Recombinant human thrombopoietin and rituximab vs. rit-
196. Isaacs C, Robert NJ, Bailey FA, et al: Randomized placebo-controlled study of recom- uximab monotherapy in corticosteroid resistant primary immune thrombocytopenia:
binant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in A multicenter randomized controlled study. American Society of Hematology annual
patients with breast cancer receiving dose-intensive cyclophosphamide and doxoru- meeting, abstract 329, 2013.
bicin. J Clin Oncol 15:3368, 1997. 223. Ghanima W, Geyer JT, Lee CS, et al: Bone marrow fibrosis in 66 immune thrombocy-
197. Vredenburgh JJ, Hussein A, Fisher D, et al: A randomized trial of recombinant human topenia patients treated with thrombopoietin receptor agonists: A single center long-
interleukin-11 following autologous bone marrow transplantation with peripheral term follow-up. Haematologica 99:937, 2014.
blood progenitor cell support in patients with breast cancer. Biol Blood Marrow Trans-
plant 4:134, 1998.

Kaushansky_chapter 111_p1813-1828.indd 1828 9/21/15 4:12 PM